mogamulizumab cutaneous T-cell lymphoma
Selected indexed studies
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. (Lancet Oncol, 2018) [PMID:30100375]
- Therapeutic advances for cutaneous T-cell lymphoma. (Br J Dermatol, 2025) [PMID:40131851]
- Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab. (Clin J Oncol Nurs, 2019) [PMID:31322628]
_Worker-drafted node — pending editorial review._
Connections
mogamulizumab cutaneous T-cell lymphoma is a side effect of
Sources
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. (2018) pubmed
- Therapeutic advances for cutaneous T-cell lymphoma. (2025) pubmed
- Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab. (2019) pubmed
- Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma. (2025) pubmed
- A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma. (2025) pubmed
- Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. (2019) pubmed
- Advancements in Cutaneous T-Cell Lymphoma Treatment: Unveiling Novel Therapeutic Avenues and Clinical Implications. (2025) pubmed
- EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023. (2023) pubmed
- Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. (2019) pubmed
- A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma. (2019) pubmed